nodes	percent_of_prediction	percent_of_DWPC	metapath
Clofarabine—Nucleic Acid Synthesis Inhibitors—Capecitabine—esophageal cancer	0.804	1	CiPCiCtD
Clofarabine—ABCG2—Carboplatin—esophageal cancer	0.0366	0.415	CbGbCtD
Clofarabine—ABCG2—Cisplatin—esophageal cancer	0.0313	0.355	CbGbCtD
Clofarabine—ABCG2—Methotrexate—esophageal cancer	0.0203	0.23	CbGbCtD
Clofarabine—RRM1—larynx—esophageal cancer	0.00565	0.319	CbGeAlD
Clofarabine—RRM2—bronchus—esophageal cancer	0.00121	0.0681	CbGeAlD
Clofarabine—RRM1—bronchus—esophageal cancer	0.001	0.0566	CbGeAlD
Clofarabine—RRM1—smooth muscle tissue—esophageal cancer	0.000982	0.0554	CbGeAlD
Clofarabine—RRM2—digestive system—esophageal cancer	0.000934	0.0526	CbGeAlD
Clofarabine—POLA1—lung—esophageal cancer	0.000816	0.046	CbGeAlD
Clofarabine—DCK—bronchus—esophageal cancer	0.00078	0.044	CbGeAlD
Clofarabine—RRM2—lung—esophageal cancer	0.00078	0.044	CbGeAlD
Clofarabine—RRM1—digestive system—esophageal cancer	0.000776	0.0437	CbGeAlD
Clofarabine—DCK—trachea—esophageal cancer	0.0007	0.0395	CbGeAlD
Clofarabine—RRM1—lung—esophageal cancer	0.000648	0.0365	CbGeAlD
Clofarabine—DCK—digestive system—esophageal cancer	0.000602	0.034	CbGeAlD
Clofarabine—POLA1—lymph node—esophageal cancer	0.000558	0.0315	CbGeAlD
Clofarabine—RRM2—lymph node—esophageal cancer	0.000533	0.0301	CbGeAlD
Clofarabine—DCK—lung—esophageal cancer	0.000503	0.0284	CbGeAlD
Clofarabine—RRM1—lymph node—esophageal cancer	0.000443	0.025	CbGeAlD
Clofarabine—DCK—lymph node—esophageal cancer	0.000344	0.0194	CbGeAlD
Clofarabine—Mucosal inflammation—Methotrexate—esophageal cancer	0.000311	0.00676	CcSEcCtD
Clofarabine—Herpes zoster—Capecitabine—esophageal cancer	0.000307	0.00668	CcSEcCtD
Clofarabine—Rash erythematous—Capecitabine—esophageal cancer	0.000302	0.00657	CcSEcCtD
Clofarabine—Pleural effusion—Capecitabine—esophageal cancer	0.000302	0.00657	CcSEcCtD
Clofarabine—Body temperature increased—Carboplatin—esophageal cancer	0.000302	0.00656	CcSEcCtD
Clofarabine—Skin exfoliation—Cisplatin—esophageal cancer	0.0003	0.00651	CcSEcCtD
Clofarabine—Fungal infection—Capecitabine—esophageal cancer	0.0003	0.00651	CcSEcCtD
Clofarabine—Hepatotoxicity—Capecitabine—esophageal cancer	0.0003	0.00651	CcSEcCtD
Clofarabine—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.00029	0.0063	CcSEcCtD
Clofarabine—Febrile neutropenia—Methotrexate—esophageal cancer	0.000286	0.00622	CcSEcCtD
Clofarabine—Polyp—Methotrexate—esophageal cancer	0.000283	0.00615	CcSEcCtD
Clofarabine—Petechiae—Capecitabine—esophageal cancer	0.000281	0.00611	CcSEcCtD
Clofarabine—ABCG2—lung—esophageal cancer	0.000281	0.0158	CbGeAlD
Clofarabine—Contusion—Capecitabine—esophageal cancer	0.000265	0.00577	CcSEcCtD
Clofarabine—Cyst—Methotrexate—esophageal cancer	0.000258	0.0056	CcSEcCtD
Clofarabine—Deafness—Cisplatin—esophageal cancer	0.000255	0.00554	CcSEcCtD
Clofarabine—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000255	0.00553	CcSEcCtD
Clofarabine—Cellulitis—Capecitabine—esophageal cancer	0.000255	0.00553	CcSEcCtD
Clofarabine—Herpes simplex—Capecitabine—esophageal cancer	0.000251	0.00546	CcSEcCtD
Clofarabine—Haematemesis—Methotrexate—esophageal cancer	0.000248	0.00539	CcSEcCtD
Clofarabine—Renal failure acute—Cisplatin—esophageal cancer	0.000247	0.00537	CcSEcCtD
Clofarabine—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000245	0.00532	CcSEcCtD
Clofarabine—Hearing impaired—Capecitabine—esophageal cancer	0.000243	0.00528	CcSEcCtD
Clofarabine—Bone pain—Capecitabine—esophageal cancer	0.000242	0.00525	CcSEcCtD
Clofarabine—Herpes zoster—Methotrexate—esophageal cancer	0.000229	0.00497	CcSEcCtD
Clofarabine—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000228	0.00495	CcSEcCtD
Clofarabine—Pleural effusion—Methotrexate—esophageal cancer	0.000225	0.00489	CcSEcCtD
Clofarabine—Fungal infection—Methotrexate—esophageal cancer	0.000223	0.00485	CcSEcCtD
Clofarabine—Hepatotoxicity—Methotrexate—esophageal cancer	0.000223	0.00485	CcSEcCtD
Clofarabine—Colitis—Capecitabine—esophageal cancer	0.000222	0.00483	CcSEcCtD
Clofarabine—Candida infection—Capecitabine—esophageal cancer	0.000221	0.0048	CcSEcCtD
Clofarabine—Skin exfoliation—Capecitabine—esophageal cancer	0.000221	0.0048	CcSEcCtD
Clofarabine—Necrosis—Methotrexate—esophageal cancer	0.00022	0.00477	CcSEcCtD
Clofarabine—Irritability—Cisplatin—esophageal cancer	0.000218	0.00473	CcSEcCtD
Clofarabine—Blood creatinine increased—Cisplatin—esophageal cancer	0.000214	0.00464	CcSEcCtD
Clofarabine—Dehydration—Cisplatin—esophageal cancer	0.000212	0.00461	CcSEcCtD
Clofarabine—Petechiae—Methotrexate—esophageal cancer	0.000209	0.00455	CcSEcCtD
Clofarabine—Mouth ulceration—Capecitabine—esophageal cancer	0.000209	0.00455	CcSEcCtD
Clofarabine—Neoplasm—Capecitabine—esophageal cancer	0.000209	0.00455	CcSEcCtD
Clofarabine—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000205	0.00446	CcSEcCtD
Clofarabine—Sepsis—Capecitabine—esophageal cancer	0.000201	0.00436	CcSEcCtD
Clofarabine—Pancreatitis—Cisplatin—esophageal cancer	0.000193	0.0042	CcSEcCtD
Clofarabine—ABCG2—lymph node—esophageal cancer	0.000192	0.0108	CbGeAlD
Clofarabine—Bone disorder—Methotrexate—esophageal cancer	0.000191	0.00415	CcSEcCtD
Clofarabine—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000189	0.00412	CcSEcCtD
Clofarabine—Deafness—Capecitabine—esophageal cancer	0.000188	0.00408	CcSEcCtD
Clofarabine—Pancytopenia—Cisplatin—esophageal cancer	0.000187	0.00407	CcSEcCtD
Clofarabine—Herpes simplex—Methotrexate—esophageal cancer	0.000187	0.00406	CcSEcCtD
Clofarabine—Hyperuricaemia—Methotrexate—esophageal cancer	0.000186	0.00404	CcSEcCtD
Clofarabine—Renal failure acute—Capecitabine—esophageal cancer	0.000182	0.00395	CcSEcCtD
Clofarabine—Adenosine monophosphate—PDE4D—esophageal cancer	0.000177	1	CrCbGaD
Clofarabine—Blood uric acid increased—Methotrexate—esophageal cancer	0.000175	0.00381	CcSEcCtD
Clofarabine—Respiratory failure—Methotrexate—esophageal cancer	0.000175	0.00381	CcSEcCtD
Clofarabine—Renal failure—Cisplatin—esophageal cancer	0.000173	0.00375	CcSEcCtD
Clofarabine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000172	0.00374	CcSEcCtD
Clofarabine—Lethargy—Capecitabine—esophageal cancer	0.000171	0.00373	CcSEcCtD
Clofarabine—Stomatitis—Cisplatin—esophageal cancer	0.000171	0.00372	CcSEcCtD
Clofarabine—Pain in extremity—Capecitabine—esophageal cancer	0.000168	0.00365	CcSEcCtD
Clofarabine—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000168	0.00365	CcSEcCtD
Clofarabine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000166	0.00361	CcSEcCtD
Clofarabine—Skin exfoliation—Methotrexate—esophageal cancer	0.000165	0.00357	CcSEcCtD
Clofarabine—Irritability—Capecitabine—esophageal cancer	0.00016	0.00348	CcSEcCtD
Clofarabine—Blood creatinine increased—Capecitabine—esophageal cancer	0.000157	0.00342	CcSEcCtD
Clofarabine—Dehydration—Capecitabine—esophageal cancer	0.000156	0.0034	CcSEcCtD
Clofarabine—Neoplasm—Methotrexate—esophageal cancer	0.000156	0.00339	CcSEcCtD
Clofarabine—Mouth ulceration—Methotrexate—esophageal cancer	0.000156	0.00339	CcSEcCtD
Clofarabine—Urinary tract disorder—Cisplatin—esophageal cancer	0.000156	0.00338	CcSEcCtD
Clofarabine—Connective tissue disorder—Cisplatin—esophageal cancer	0.000155	0.00337	CcSEcCtD
Clofarabine—Urethral disorder—Cisplatin—esophageal cancer	0.000155	0.00336	CcSEcCtD
Clofarabine—Dry skin—Capecitabine—esophageal cancer	0.000154	0.00335	CcSEcCtD
Clofarabine—Abdominal pain upper—Capecitabine—esophageal cancer	0.000153	0.00333	CcSEcCtD
Clofarabine—Pulmonary oedema—Methotrexate—esophageal cancer	0.000153	0.00333	CcSEcCtD
Clofarabine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000151	0.00329	CcSEcCtD
Clofarabine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000151	0.00329	CcSEcCtD
Clofarabine—Sepsis—Methotrexate—esophageal cancer	0.00015	0.00325	CcSEcCtD
Clofarabine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000148	0.00322	CcSEcCtD
Clofarabine—Cardiac disorder—Cisplatin—esophageal cancer	0.000146	0.00318	CcSEcCtD
Clofarabine—Flushing—Cisplatin—esophageal cancer	0.000146	0.00318	CcSEcCtD
Clofarabine—Influenza—Capecitabine—esophageal cancer	0.000145	0.00316	CcSEcCtD
Clofarabine—Immune system disorder—Cisplatin—esophageal cancer	0.000142	0.0031	CcSEcCtD
Clofarabine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000142	0.00309	CcSEcCtD
Clofarabine—Alopecia—Cisplatin—esophageal cancer	0.000139	0.00303	CcSEcCtD
Clofarabine—Pancytopenia—Capecitabine—esophageal cancer	0.000138	0.003	CcSEcCtD
Clofarabine—Erythema—Cisplatin—esophageal cancer	0.000137	0.00298	CcSEcCtD
Clofarabine—Malnutrition—Cisplatin—esophageal cancer	0.000137	0.00298	CcSEcCtD
Clofarabine—Neutropenia—Capecitabine—esophageal cancer	0.000136	0.00295	CcSEcCtD
Clofarabine—Renal failure acute—Methotrexate—esophageal cancer	0.000135	0.00294	CcSEcCtD
Clofarabine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000135	0.00293	CcSEcCtD
Clofarabine—Weight decreased—Capecitabine—esophageal cancer	0.000131	0.00286	CcSEcCtD
Clofarabine—Pneumonia—Capecitabine—esophageal cancer	0.00013	0.00283	CcSEcCtD
Clofarabine—Infestation—Capecitabine—esophageal cancer	0.000129	0.00281	CcSEcCtD
Clofarabine—Infestation NOS—Capecitabine—esophageal cancer	0.000129	0.00281	CcSEcCtD
Clofarabine—Tremor—Cisplatin—esophageal cancer	0.000129	0.00279	CcSEcCtD
Clofarabine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000128	0.00279	CcSEcCtD
Clofarabine—Lethargy—Methotrexate—esophageal cancer	0.000128	0.00277	CcSEcCtD
Clofarabine—Renal failure—Capecitabine—esophageal cancer	0.000127	0.00277	CcSEcCtD
Clofarabine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000127	0.00276	CcSEcCtD
Clofarabine—Anaemia—Cisplatin—esophageal cancer	0.000127	0.00276	CcSEcCtD
Clofarabine—Stomatitis—Capecitabine—esophageal cancer	0.000126	0.00274	CcSEcCtD
Clofarabine—Jaundice—Capecitabine—esophageal cancer	0.000126	0.00274	CcSEcCtD
Clofarabine—Haematuria—Capecitabine—esophageal cancer	0.000123	0.00268	CcSEcCtD
Clofarabine—Leukopenia—Cisplatin—esophageal cancer	0.000123	0.00267	CcSEcCtD
Clofarabine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000122	0.00266	CcSEcCtD
Clofarabine—Epistaxis—Capecitabine—esophageal cancer	0.000122	0.00265	CcSEcCtD
Clofarabine—Irritability—Methotrexate—esophageal cancer	0.000119	0.00259	CcSEcCtD
Clofarabine—Myalgia—Cisplatin—esophageal cancer	0.000117	0.00254	CcSEcCtD
Clofarabine—Haemoglobin—Capecitabine—esophageal cancer	0.000117	0.00254	CcSEcCtD
Clofarabine—Anxiety—Cisplatin—esophageal cancer	0.000116	0.00253	CcSEcCtD
Clofarabine—Haemorrhage—Capecitabine—esophageal cancer	0.000116	0.00253	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000116	0.00252	CcSEcCtD
Clofarabine—Urinary tract disorder—Capecitabine—esophageal cancer	0.000115	0.00249	CcSEcCtD
Clofarabine—Oedema peripheral—Capecitabine—esophageal cancer	0.000115	0.00249	CcSEcCtD
Clofarabine—Connective tissue disorder—Capecitabine—esophageal cancer	0.000114	0.00248	CcSEcCtD
Clofarabine—Urethral disorder—Capecitabine—esophageal cancer	0.000114	0.00248	CcSEcCtD
Clofarabine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000113	0.00245	CcSEcCtD
Clofarabine—Oedema—Cisplatin—esophageal cancer	0.000112	0.00243	CcSEcCtD
Clofarabine—Infection—Cisplatin—esophageal cancer	0.000111	0.00242	CcSEcCtD
Clofarabine—Erythema multiforme—Capecitabine—esophageal cancer	0.00011	0.00239	CcSEcCtD
Clofarabine—Nervous system disorder—Cisplatin—esophageal cancer	0.00011	0.00239	CcSEcCtD
Clofarabine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00011	0.00238	CcSEcCtD
Clofarabine—Tachycardia—Cisplatin—esophageal cancer	0.000109	0.00238	CcSEcCtD
Clofarabine—Skin disorder—Cisplatin—esophageal cancer	0.000109	0.00236	CcSEcCtD
Clofarabine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000108	0.00235	CcSEcCtD
Clofarabine—Flushing—Capecitabine—esophageal cancer	0.000108	0.00234	CcSEcCtD
Clofarabine—Cardiac disorder—Capecitabine—esophageal cancer	0.000108	0.00234	CcSEcCtD
Clofarabine—Anorexia—Cisplatin—esophageal cancer	0.000107	0.00232	CcSEcCtD
Clofarabine—Pancreatitis—Methotrexate—esophageal cancer	0.000106	0.0023	CcSEcCtD
Clofarabine—Angiopathy—Capecitabine—esophageal cancer	0.000105	0.00229	CcSEcCtD
Clofarabine—Immune system disorder—Capecitabine—esophageal cancer	0.000105	0.00228	CcSEcCtD
Clofarabine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000105	0.00228	CcSEcCtD
Clofarabine—Hypotension—Cisplatin—esophageal cancer	0.000105	0.00227	CcSEcCtD
Clofarabine—Chills—Capecitabine—esophageal cancer	0.000104	0.00227	CcSEcCtD
Clofarabine—Alopecia—Capecitabine—esophageal cancer	0.000103	0.00223	CcSEcCtD
Clofarabine—Pancytopenia—Methotrexate—esophageal cancer	0.000103	0.00223	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000102	0.00222	CcSEcCtD
Clofarabine—Mental disorder—Capecitabine—esophageal cancer	0.000102	0.00221	CcSEcCtD
Clofarabine—Malnutrition—Capecitabine—esophageal cancer	0.000101	0.0022	CcSEcCtD
Clofarabine—Erythema—Capecitabine—esophageal cancer	0.000101	0.0022	CcSEcCtD
Clofarabine—Neutropenia—Methotrexate—esophageal cancer	0.000101	0.0022	CcSEcCtD
Clofarabine—Paraesthesia—Cisplatin—esophageal cancer	0.000101	0.00219	CcSEcCtD
Clofarabine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.0001	0.00218	CcSEcCtD
Clofarabine—Dyspnoea—Cisplatin—esophageal cancer	9.99e-05	0.00217	CcSEcCtD
Clofarabine—Back pain—Capecitabine—esophageal cancer	9.79e-05	0.00213	CcSEcCtD
Clofarabine—Decreased appetite—Cisplatin—esophageal cancer	9.74e-05	0.00212	CcSEcCtD
Clofarabine—Pneumonia—Methotrexate—esophageal cancer	9.7e-05	0.00211	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Cisplatin—esophageal cancer	9.67e-05	0.0021	CcSEcCtD
Clofarabine—Infestation NOS—Methotrexate—esophageal cancer	9.64e-05	0.00209	CcSEcCtD
Clofarabine—Infestation—Methotrexate—esophageal cancer	9.64e-05	0.00209	CcSEcCtD
Clofarabine—Pain—Cisplatin—esophageal cancer	9.58e-05	0.00208	CcSEcCtD
Clofarabine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	9.56e-05	0.00208	CcSEcCtD
Clofarabine—Tremor—Capecitabine—esophageal cancer	9.48e-05	0.00206	CcSEcCtD
Clofarabine—Renal failure—Methotrexate—esophageal cancer	9.48e-05	0.00206	CcSEcCtD
Clofarabine—Stomatitis—Methotrexate—esophageal cancer	9.4e-05	0.00204	CcSEcCtD
Clofarabine—Anaemia—Capecitabine—esophageal cancer	9.35e-05	0.00203	CcSEcCtD
Clofarabine—Feeling abnormal—Cisplatin—esophageal cancer	9.23e-05	0.00201	CcSEcCtD
Clofarabine—Haematuria—Methotrexate—esophageal cancer	9.19e-05	0.002	CcSEcCtD
Clofarabine—Hepatobiliary disease—Methotrexate—esophageal cancer	9.12e-05	0.00198	CcSEcCtD
Clofarabine—Epistaxis—Methotrexate—esophageal cancer	9.09e-05	0.00198	CcSEcCtD
Clofarabine—Leukopenia—Capecitabine—esophageal cancer	9.06e-05	0.00197	CcSEcCtD
Clofarabine—Body temperature increased—Cisplatin—esophageal cancer	8.86e-05	0.00192	CcSEcCtD
Clofarabine—Cough—Capecitabine—esophageal cancer	8.83e-05	0.00192	CcSEcCtD
Clofarabine—Hypertension—Capecitabine—esophageal cancer	8.74e-05	0.0019	CcSEcCtD
Clofarabine—Haemoglobin—Methotrexate—esophageal cancer	8.7e-05	0.00189	CcSEcCtD
Clofarabine—Haemorrhage—Methotrexate—esophageal cancer	8.65e-05	0.00188	CcSEcCtD
Clofarabine—Myalgia—Capecitabine—esophageal cancer	8.61e-05	0.00187	CcSEcCtD
Clofarabine—Arthralgia—Capecitabine—esophageal cancer	8.61e-05	0.00187	CcSEcCtD
Clofarabine—Anxiety—Capecitabine—esophageal cancer	8.58e-05	0.00187	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	8.56e-05	0.00186	CcSEcCtD
Clofarabine—Urinary tract disorder—Methotrexate—esophageal cancer	8.55e-05	0.00186	CcSEcCtD
Clofarabine—Urethral disorder—Methotrexate—esophageal cancer	8.48e-05	0.00184	CcSEcCtD
Clofarabine—Oedema—Capecitabine—esophageal cancer	8.26e-05	0.00179	CcSEcCtD
Clofarabine—Hypersensitivity—Cisplatin—esophageal cancer	8.25e-05	0.00179	CcSEcCtD
Clofarabine—Infection—Capecitabine—esophageal cancer	8.2e-05	0.00178	CcSEcCtD
Clofarabine—Erythema multiforme—Methotrexate—esophageal cancer	8.18e-05	0.00178	CcSEcCtD
Clofarabine—Nervous system disorder—Capecitabine—esophageal cancer	8.1e-05	0.00176	CcSEcCtD
Clofarabine—Thrombocytopenia—Capecitabine—esophageal cancer	8.09e-05	0.00176	CcSEcCtD
Clofarabine—Tachycardia—Capecitabine—esophageal cancer	8.06e-05	0.00175	CcSEcCtD
Clofarabine—Asthenia—Cisplatin—esophageal cancer	8.04e-05	0.00175	CcSEcCtD
Clofarabine—Cardiac disorder—Methotrexate—esophageal cancer	8.03e-05	0.00175	CcSEcCtD
Clofarabine—Skin disorder—Capecitabine—esophageal cancer	8.02e-05	0.00174	CcSEcCtD
Clofarabine—Hyperhidrosis—Capecitabine—esophageal cancer	7.98e-05	0.00173	CcSEcCtD
Clofarabine—POLA1—Mitotic M-M/G1 phases—MAD2L1—esophageal cancer	7.94e-05	0.00182	CbGpPWpGaD
Clofarabine—POLA1—E2F transcription factor network—CDKN1A—esophageal cancer	7.91e-05	0.00182	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	7.91e-05	0.00182	CbGpPWpGaD
Clofarabine—Anorexia—Capecitabine—esophageal cancer	7.87e-05	0.00171	CcSEcCtD
Clofarabine—Angiopathy—Methotrexate—esophageal cancer	7.85e-05	0.00171	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	7.83e-05	0.0018	CbGpPWpGaD
Clofarabine—Immune system disorder—Methotrexate—esophageal cancer	7.82e-05	0.0017	CcSEcCtD
Clofarabine—Mediastinal disorder—Methotrexate—esophageal cancer	7.8e-05	0.00169	CcSEcCtD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	7.79e-05	0.00179	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—MAD2L1—esophageal cancer	7.77e-05	0.00178	CbGpPWpGaD
Clofarabine—Chills—Methotrexate—esophageal cancer	7.76e-05	0.00169	CcSEcCtD
Clofarabine—Hypotension—Capecitabine—esophageal cancer	7.72e-05	0.00168	CcSEcCtD
Clofarabine—RRM1—Metabolism—CA1—esophageal cancer	7.71e-05	0.00177	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—SLC10A2—esophageal cancer	7.71e-05	0.00177	CbGpPWpGaD
Clofarabine—Diarrhoea—Cisplatin—esophageal cancer	7.67e-05	0.00167	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	7.66e-05	0.00176	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	7.66e-05	0.00176	CbGpPWpGaD
Clofarabine—Alopecia—Methotrexate—esophageal cancer	7.65e-05	0.00166	CcSEcCtD
Clofarabine—RRM2—Cell Cycle, Mitotic—PSME2—esophageal cancer	7.63e-05	0.00175	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—PSME1—esophageal cancer	7.63e-05	0.00175	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	7.61e-05	0.00175	CbGpPWpGaD
Clofarabine—ABCG2—HIF-2-alpha transcription factor network—EP300—esophageal cancer	7.58e-05	0.00174	CbGpPWpGaD
Clofarabine—Mental disorder—Methotrexate—esophageal cancer	7.58e-05	0.00165	CcSEcCtD
Clofarabine—Malnutrition—Methotrexate—esophageal cancer	7.53e-05	0.00164	CcSEcCtD
Clofarabine—Erythema—Methotrexate—esophageal cancer	7.53e-05	0.00164	CcSEcCtD
Clofarabine—POLA1—E2F transcription factor network—EP300—esophageal cancer	7.53e-05	0.00173	CbGpPWpGaD
Clofarabine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	7.52e-05	0.00163	CcSEcCtD
Clofarabine—RRM2—Metabolism—BLVRB—esophageal cancer	7.47e-05	0.00171	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—SLC52A3—esophageal cancer	7.47e-05	0.00171	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	7.44e-05	0.00171	CbGpPWpGaD
Clofarabine—Paraesthesia—Capecitabine—esophageal cancer	7.42e-05	0.00161	CcSEcCtD
Clofarabine—Dyspnoea—Capecitabine—esophageal cancer	7.36e-05	0.0016	CcSEcCtD
Clofarabine—RRM2—Mitotic G1-G1/S phases—CCND1—esophageal cancer	7.31e-05	0.00168	CbGpPWpGaD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	7.29e-05	0.00167	CbGpPWpGaD
Clofarabine—Back pain—Methotrexate—esophageal cancer	7.29e-05	0.00158	CcSEcCtD
Clofarabine—POLA1—S Phase—RB1—esophageal cancer	7.25e-05	0.00166	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	7.25e-05	0.00166	CbGpPWpGaD
Clofarabine—Decreased appetite—Capecitabine—esophageal cancer	7.18e-05	0.00156	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Capecitabine—esophageal cancer	7.13e-05	0.00155	CcSEcCtD
Clofarabine—Vomiting—Cisplatin—esophageal cancer	7.12e-05	0.00155	CcSEcCtD
Clofarabine—Fatigue—Capecitabine—esophageal cancer	7.12e-05	0.00155	CcSEcCtD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	7.1e-05	0.00163	CbGpPWpGaD
Clofarabine—RRM2—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	7.07e-05	0.00162	CbGpPWpGaD
Clofarabine—Rash—Cisplatin—esophageal cancer	7.06e-05	0.00153	CcSEcCtD
Clofarabine—Pain—Capecitabine—esophageal cancer	7.06e-05	0.00153	CcSEcCtD
Clofarabine—Dermatitis—Cisplatin—esophageal cancer	7.06e-05	0.00153	CcSEcCtD
Clofarabine—RRM1—Metabolism—CA2—esophageal cancer	7.05e-05	0.00162	CbGpPWpGaD
Clofarabine—DCK—Metabolism—SLC52A3—esophageal cancer	6.98e-05	0.0016	CbGpPWpGaD
Clofarabine—DCK—Metabolism—BLVRB—esophageal cancer	6.98e-05	0.0016	CbGpPWpGaD
Clofarabine—POLA1—Mitotic M-M/G1 phases—PSME2—esophageal cancer	6.98e-05	0.0016	CbGpPWpGaD
Clofarabine—POLA1—Mitotic M-M/G1 phases—PSME1—esophageal cancer	6.98e-05	0.0016	CbGpPWpGaD
Clofarabine—Anaemia—Methotrexate—esophageal cancer	6.96e-05	0.00151	CcSEcCtD
Clofarabine—RRM2—G1/S Transition—MYC—esophageal cancer	6.96e-05	0.0016	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—BUB1B—esophageal cancer	6.94e-05	0.00159	CbGpPWpGaD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	6.87e-05	0.00158	CbGpPWpGaD
Clofarabine—RRM2—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	6.84e-05	0.00157	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—PSME2—esophageal cancer	6.82e-05	0.00157	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—PSME1—esophageal cancer	6.82e-05	0.00157	CbGpPWpGaD
Clofarabine—Feeling abnormal—Capecitabine—esophageal cancer	6.81e-05	0.00148	CcSEcCtD
Clofarabine—Gastrointestinal pain—Capecitabine—esophageal cancer	6.75e-05	0.00147	CcSEcCtD
Clofarabine—Leukopenia—Methotrexate—esophageal cancer	6.74e-05	0.00147	CcSEcCtD
Clofarabine—POLA1—Mitotic G1-G1/S phases—RB1—esophageal cancer	6.73e-05	0.00155	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	6.73e-05	0.00154	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	6.72e-05	0.00154	CbGpPWpGaD
Clofarabine—Nausea—Cisplatin—esophageal cancer	6.65e-05	0.00145	CcSEcCtD
Clofarabine—Cough—Methotrexate—esophageal cancer	6.57e-05	0.00143	CcSEcCtD
Clofarabine—RRM1—Metabolism—ADH7—esophageal cancer	6.56e-05	0.00151	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PLCE1—esophageal cancer	6.56e-05	0.00151	CbGpPWpGaD
Clofarabine—POLA1—E2F transcription factor network—MYC—esophageal cancer	6.56e-05	0.00151	CbGpPWpGaD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	6.55e-05	0.0015	CbGpPWpGaD
Clofarabine—Abdominal pain—Capecitabine—esophageal cancer	6.53e-05	0.00142	CcSEcCtD
Clofarabine—Body temperature increased—Capecitabine—esophageal cancer	6.53e-05	0.00142	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	6.51e-05	0.00149	CbGpPWpGaD
Clofarabine—Myalgia—Methotrexate—esophageal cancer	6.41e-05	0.00139	CcSEcCtD
Clofarabine—Arthralgia—Methotrexate—esophageal cancer	6.41e-05	0.00139	CcSEcCtD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	6.39e-05	0.00147	CbGpPWpGaD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	6.37e-05	0.00138	CcSEcCtD
Clofarabine—POLA1—Synthesis of DNA—CDKN1A—esophageal cancer	6.35e-05	0.00146	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—SLC10A2—esophageal cancer	6.35e-05	0.00146	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—CA1—esophageal cancer	6.35e-05	0.00146	CbGpPWpGaD
Clofarabine—POLA1—Mitotic M-M/G1 phases—BUB1B—esophageal cancer	6.35e-05	0.00146	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—BUB1B—esophageal cancer	6.21e-05	0.00143	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	6.19e-05	0.00142	CbGpPWpGaD
Clofarabine—Infection—Methotrexate—esophageal cancer	6.11e-05	0.00133	CcSEcCtD
Clofarabine—Hypersensitivity—Capecitabine—esophageal cancer	6.08e-05	0.00132	CcSEcCtD
Clofarabine—Nervous system disorder—Methotrexate—esophageal cancer	6.03e-05	0.00131	CcSEcCtD
Clofarabine—Thrombocytopenia—Methotrexate—esophageal cancer	6.02e-05	0.00131	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—HIST1H2BM—esophageal cancer	6.01e-05	0.00138	CbGpPWpGaD
Clofarabine—Skin disorder—Methotrexate—esophageal cancer	5.97e-05	0.0013	CcSEcCtD
Clofarabine—POLA1—DNA Replication—CDKN1A—esophageal cancer	5.96e-05	0.00137	CbGpPWpGaD
Clofarabine—Hyperhidrosis—Methotrexate—esophageal cancer	5.94e-05	0.00129	CcSEcCtD
Clofarabine—POLA1—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	5.94e-05	0.00136	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CA1—esophageal cancer	5.94e-05	0.00136	CbGpPWpGaD
Clofarabine—DCK—Metabolism—SLC10A2—esophageal cancer	5.94e-05	0.00136	CbGpPWpGaD
Clofarabine—Asthenia—Capecitabine—esophageal cancer	5.93e-05	0.00129	CcSEcCtD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	5.92e-05	0.00136	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CHEK2—esophageal cancer	5.91e-05	0.00136	CbGpPWpGaD
Clofarabine—RRM2—Mitotic G1-G1/S phases—MYC—esophageal cancer	5.86e-05	0.00135	CbGpPWpGaD
Clofarabine—Anorexia—Methotrexate—esophageal cancer	5.86e-05	0.00127	CcSEcCtD
Clofarabine—Pruritus—Capecitabine—esophageal cancer	5.84e-05	0.00127	CcSEcCtD
Clofarabine—RRM2—Metabolism—CA2—esophageal cancer	5.81e-05	0.00133	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—ADH1B—esophageal cancer	5.75e-05	0.00132	CbGpPWpGaD
Clofarabine—Hypotension—Methotrexate—esophageal cancer	5.74e-05	0.00125	CcSEcCtD
Clofarabine—POLA1—G1/S Transition—CDKN1A—esophageal cancer	5.74e-05	0.00132	CbGpPWpGaD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	5.7e-05	0.00131	CbGpPWpGaD
Clofarabine—Diarrhoea—Capecitabine—esophageal cancer	5.65e-05	0.00123	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	5.6e-05	0.00122	CcSEcCtD
Clofarabine—ABCG2—Fluoropyrimidine Activity—TP53—esophageal cancer	5.56e-05	0.00128	CbGpPWpGaD
Clofarabine—Paraesthesia—Methotrexate—esophageal cancer	5.52e-05	0.0012	CcSEcCtD
Clofarabine—RRM1—Metabolism—TYMP—esophageal cancer	5.5e-05	0.00126	CbGpPWpGaD
Clofarabine—Dyspnoea—Methotrexate—esophageal cancer	5.48e-05	0.00119	CcSEcCtD
Clofarabine—Somnolence—Methotrexate—esophageal cancer	5.47e-05	0.00119	CcSEcCtD
Clofarabine—Dizziness—Capecitabine—esophageal cancer	5.46e-05	0.00119	CcSEcCtD
Clofarabine—DCK—Metabolism—CA2—esophageal cancer	5.43e-05	0.00125	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PLCE1—esophageal cancer	5.4e-05	0.00124	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ADH7—esophageal cancer	5.4e-05	0.00124	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	5.39e-05	0.00124	CbGpPWpGaD
Clofarabine—POLA1—S Phase—CCND1—esophageal cancer	5.39e-05	0.00124	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—CYP26A1—esophageal cancer	5.35e-05	0.00123	CbGpPWpGaD
Clofarabine—Decreased appetite—Methotrexate—esophageal cancer	5.34e-05	0.00116	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—MAD2L1—esophageal cancer	5.31e-05	0.00122	CbGpPWpGaD
Clofarabine—Gastrointestinal disorder—Methotrexate—esophageal cancer	5.31e-05	0.00115	CcSEcCtD
Clofarabine—Fatigue—Methotrexate—esophageal cancer	5.3e-05	0.00115	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	5.28e-05	0.00121	CbGpPWpGaD
Clofarabine—Pain—Methotrexate—esophageal cancer	5.26e-05	0.00114	CcSEcCtD
Clofarabine—Vomiting—Capecitabine—esophageal cancer	5.25e-05	0.00114	CcSEcCtD
Clofarabine—POLA1—Cell Cycle, Mitotic—PSME2—esophageal cancer	5.22e-05	0.0012	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—PSME1—esophageal cancer	5.22e-05	0.0012	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—ALOX15—esophageal cancer	5.21e-05	0.0012	CbGpPWpGaD
Clofarabine—POLA1—S Phase—CDKN1A—esophageal cancer	5.21e-05	0.0012	CbGpPWpGaD
Clofarabine—Rash—Capecitabine—esophageal cancer	5.21e-05	0.00113	CcSEcCtD
Clofarabine—Dermatitis—Capecitabine—esophageal cancer	5.2e-05	0.00113	CcSEcCtD
Clofarabine—Headache—Capecitabine—esophageal cancer	5.17e-05	0.00112	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	5.14e-05	0.00118	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	5.12e-05	0.00118	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	5.07e-05	0.00116	CbGpPWpGaD
Clofarabine—Feeling abnormal—Methotrexate—esophageal cancer	5.07e-05	0.0011	CcSEcCtD
Clofarabine—DCK—Metabolism—PLCE1—esophageal cancer	5.05e-05	0.00116	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ADH7—esophageal cancer	5.05e-05	0.00116	CbGpPWpGaD
Clofarabine—Gastrointestinal pain—Methotrexate—esophageal cancer	5.03e-05	0.00109	CcSEcCtD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CCND1—esophageal cancer	5e-05	0.00115	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—GSTO1—esophageal cancer	4.97e-05	0.00114	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—TPI1—esophageal cancer	4.97e-05	0.00114	CbGpPWpGaD
Clofarabine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	4.93e-05	0.00113	CbGpPWpGaD
Clofarabine—Nausea—Capecitabine—esophageal cancer	4.91e-05	0.00107	CcSEcCtD
Clofarabine—Abdominal pain—Methotrexate—esophageal cancer	4.86e-05	0.00106	CcSEcCtD
Clofarabine—Body temperature increased—Methotrexate—esophageal cancer	4.86e-05	0.00106	CcSEcCtD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	4.84e-05	0.00111	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	4.77e-05	0.00109	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—ALDOB—esophageal cancer	4.77e-05	0.00109	CbGpPWpGaD
Clofarabine—POLA1—G1/S Transition—MYC—esophageal cancer	4.76e-05	0.00109	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—BUB1B—esophageal cancer	4.75e-05	0.00109	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ADH1B—esophageal cancer	4.74e-05	0.00109	CbGpPWpGaD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	4.68e-05	0.00107	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—PSME1—esophageal cancer	4.67e-05	0.00107	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—PSME2—esophageal cancer	4.67e-05	0.00107	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—GAPDH—esophageal cancer	4.59e-05	0.00105	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	4.58e-05	0.00105	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—CRABP1—esophageal cancer	4.55e-05	0.00104	CbGpPWpGaD
Clofarabine—Hypersensitivity—Methotrexate—esophageal cancer	4.53e-05	0.000984	CcSEcCtD
Clofarabine—RRM2—Metabolism—TYMP—esophageal cancer	4.53e-05	0.00104	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	4.52e-05	0.00104	CbGpPWpGaD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—EP300—esophageal cancer	4.46e-05	0.00102	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	4.43e-05	0.00102	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ADH1B—esophageal cancer	4.43e-05	0.00102	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	4.41e-05	0.00101	CbGpPWpGaD
Clofarabine—Asthenia—Methotrexate—esophageal cancer	4.41e-05	0.000958	CcSEcCtD
Clofarabine—RRM2—Metabolism—CYP26A1—esophageal cancer	4.4e-05	0.00101	CbGpPWpGaD
Clofarabine—Pruritus—Methotrexate—esophageal cancer	4.35e-05	0.000945	CcSEcCtD
Clofarabine—RRM1—Metabolism—GNG7—esophageal cancer	4.32e-05	0.000993	CbGpPWpGaD
Clofarabine—POLA1—S Phase—MYC—esophageal cancer	4.32e-05	0.000992	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—AQP3—esophageal cancer	4.31e-05	0.00099	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ALOX15—esophageal cancer	4.29e-05	0.000985	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	4.29e-05	0.000984	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—BUB1B—esophageal cancer	4.25e-05	0.000975	CbGpPWpGaD
Clofarabine—DCK—Metabolism—TYMP—esophageal cancer	4.23e-05	0.000971	CbGpPWpGaD
Clofarabine—Diarrhoea—Methotrexate—esophageal cancer	4.21e-05	0.000914	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	4.19e-05	0.000962	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	4.13e-05	0.000949	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	4.13e-05	0.000949	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CYP26A1—esophageal cancer	4.11e-05	0.000945	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—TPI1—esophageal cancer	4.09e-05	0.00094	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—GSTO1—esophageal cancer	4.09e-05	0.00094	CbGpPWpGaD
Clofarabine—Dizziness—Methotrexate—esophageal cancer	4.07e-05	0.000883	CcSEcCtD
Clofarabine—RRM1—Metabolism—ALDH2—esophageal cancer	4.05e-05	0.00093	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CHEK2—esophageal cancer	4.04e-05	0.000927	CbGpPWpGaD
Clofarabine—POLA1—Mitotic G1-G1/S phases—MYC—esophageal cancer	4.01e-05	0.000921	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ALOX15—esophageal cancer	4.01e-05	0.00092	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ALDOB—esophageal cancer	3.92e-05	0.000901	CbGpPWpGaD
Clofarabine—Vomiting—Methotrexate—esophageal cancer	3.91e-05	0.000849	CcSEcCtD
Clofarabine—Rash—Methotrexate—esophageal cancer	3.88e-05	0.000842	CcSEcCtD
Clofarabine—Dermatitis—Methotrexate—esophageal cancer	3.87e-05	0.000842	CcSEcCtD
Clofarabine—RRM1—Metabolism—GSTT1—esophageal cancer	3.85e-05	0.000885	CbGpPWpGaD
Clofarabine—Headache—Methotrexate—esophageal cancer	3.85e-05	0.000837	CcSEcCtD
Clofarabine—DCK—Metabolism—TPI1—esophageal cancer	3.83e-05	0.000878	CbGpPWpGaD
Clofarabine—DCK—Metabolism—GSTO1—esophageal cancer	3.83e-05	0.000878	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—CYP2A6—esophageal cancer	3.81e-05	0.000875	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.79e-05	0.000869	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—GAPDH—esophageal cancer	3.78e-05	0.000867	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—CRABP1—esophageal cancer	3.74e-05	0.000859	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ALDOB—esophageal cancer	3.67e-05	0.000842	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.66e-05	0.000841	CbGpPWpGaD
Clofarabine—Nausea—Methotrexate—esophageal cancer	3.65e-05	0.000794	CcSEcCtD
Clofarabine—RRM1—Metabolism—ENO1—esophageal cancer	3.61e-05	0.000829	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PTGS1—esophageal cancer	3.61e-05	0.000829	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—RB1—esophageal cancer	3.61e-05	0.000829	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—GNG7—esophageal cancer	3.56e-05	0.000817	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PSME1—esophageal cancer	3.56e-05	0.000817	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PSME2—esophageal cancer	3.56e-05	0.000817	CbGpPWpGaD
Clofarabine—DCK—Metabolism—GAPDH—esophageal cancer	3.53e-05	0.00081	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CRABP1—esophageal cancer	3.5e-05	0.000803	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.49e-05	0.0008	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ALDH2—esophageal cancer	3.34e-05	0.000766	CbGpPWpGaD
Clofarabine—DCK—Metabolism—GNG7—esophageal cancer	3.33e-05	0.000764	CbGpPWpGaD
Clofarabine—POLA1—Mitotic M-M/G1 phases—RB1—esophageal cancer	3.3e-05	0.000758	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—RB1—esophageal cancer	3.23e-05	0.000741	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—GSTT1—esophageal cancer	3.17e-05	0.000729	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	3.17e-05	0.000728	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—CYP2A6—esophageal cancer	3.14e-05	0.00072	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	3.13e-05	0.000719	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ALDH2—esophageal cancer	3.12e-05	0.000716	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—CYP1B1—esophageal cancer	3.07e-05	0.000705	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.04e-05	0.000697	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ENO1—esophageal cancer	2.97e-05	0.000683	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PTGS1—esophageal cancer	2.97e-05	0.000683	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.97e-05	0.000682	CbGpPWpGaD
Clofarabine—DCK—Metabolism—GSTT1—esophageal cancer	2.97e-05	0.000681	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CYP2A6—esophageal cancer	2.93e-05	0.000673	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PSME2—esophageal cancer	2.93e-05	0.000673	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PSME1—esophageal cancer	2.93e-05	0.000673	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—CYP19A1—esophageal cancer	2.89e-05	0.000663	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—GNG7—esophageal cancer	2.84e-05	0.000653	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CDKN2A—esophageal cancer	2.84e-05	0.000651	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—BLVRB—esophageal cancer	2.79e-05	0.000641	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—SLC52A3—esophageal cancer	2.79e-05	0.000641	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ENO1—esophageal cancer	2.78e-05	0.000638	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PTGS1—esophageal cancer	2.78e-05	0.000638	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PSME2—esophageal cancer	2.74e-05	0.000629	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PSME1—esophageal cancer	2.74e-05	0.000629	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CCND1—esophageal cancer	2.68e-05	0.000615	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—HMOX1—esophageal cancer	2.63e-05	0.000605	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	2.59e-05	0.000595	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.58e-05	0.000592	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—CYP1B1—esophageal cancer	2.53e-05	0.000581	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—ABCB1—esophageal cancer	2.53e-05	0.000581	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.49e-05	0.000573	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—RB1—esophageal cancer	2.47e-05	0.000567	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—EP300—esophageal cancer	2.47e-05	0.000566	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CCND1—esophageal cancer	2.4e-05	0.00055	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—CYP19A1—esophageal cancer	2.38e-05	0.000546	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—SLC10A2—esophageal cancer	2.38e-05	0.000545	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CA1—esophageal cancer	2.38e-05	0.000545	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CYP1B1—esophageal cancer	2.36e-05	0.000542	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CDKN1A—esophageal cancer	2.32e-05	0.000532	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CYP19A1—esophageal cancer	2.22e-05	0.00051	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—RB1—esophageal cancer	2.21e-05	0.000507	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—EP300—esophageal cancer	2.21e-05	0.000506	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CA2—esophageal cancer	2.17e-05	0.000499	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	2.17e-05	0.000498	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—HMOX1—esophageal cancer	2.17e-05	0.000498	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—MYC—esophageal cancer	2.15e-05	0.000494	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ABCB1—esophageal cancer	2.08e-05	0.000478	CbGpPWpGaD
Clofarabine—DCK—Metabolism—HMOX1—esophageal cancer	2.03e-05	0.000465	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PLCE1—esophageal cancer	2.02e-05	0.000464	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ADH7—esophageal cancer	2.02e-05	0.000464	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ABCB1—esophageal cancer	1.95e-05	0.000447	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CDKN2A—esophageal cancer	1.94e-05	0.000445	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—MYC—esophageal cancer	1.92e-05	0.000441	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CCND1—esophageal cancer	1.83e-05	0.000421	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	1.77e-05	0.000407	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ADH1B—esophageal cancer	1.77e-05	0.000407	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.73e-05	0.000398	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—TYMP—esophageal cancer	1.69e-05	0.000389	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—CREBBP—esophageal cancer	1.69e-05	0.000388	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—EP300—esophageal cancer	1.69e-05	0.000387	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	1.66e-05	0.000382	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CYP26A1—esophageal cancer	1.65e-05	0.000378	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CCND1—esophageal cancer	1.64e-05	0.000376	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ALOX15—esophageal cancer	1.6e-05	0.000368	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CDKN1A—esophageal cancer	1.59e-05	0.000364	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—TP53—esophageal cancer	1.58e-05	0.000362	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—GSTO1—esophageal cancer	1.53e-05	0.000351	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—TPI1—esophageal cancer	1.53e-05	0.000351	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—NOS3—esophageal cancer	1.51e-05	0.000347	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—EP300—esophageal cancer	1.51e-05	0.000346	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—MYC—esophageal cancer	1.47e-05	0.000338	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ALDOB—esophageal cancer	1.47e-05	0.000337	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—GAPDH—esophageal cancer	1.41e-05	0.000324	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CRABP1—esophageal cancer	1.4e-05	0.000321	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—CREBBP—esophageal cancer	1.39e-05	0.00032	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PTGS2—esophageal cancer	1.38e-05	0.000318	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—GNG7—esophageal cancer	1.33e-05	0.000306	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—MYC—esophageal cancer	1.32e-05	0.000302	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CREBBP—esophageal cancer	1.3e-05	0.000299	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ALDH2—esophageal cancer	1.25e-05	0.000286	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—NOS3—esophageal cancer	1.25e-05	0.000286	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—GSTT1—esophageal cancer	1.19e-05	0.000272	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CYP2A6—esophageal cancer	1.17e-05	0.000269	CbGpPWpGaD
Clofarabine—DCK—Metabolism—NOS3—esophageal cancer	1.16e-05	0.000267	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—EP300—esophageal cancer	1.15e-05	0.000264	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PTGS2—esophageal cancer	1.14e-05	0.000262	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ENO1—esophageal cancer	1.11e-05	0.000255	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PTGS1—esophageal cancer	1.11e-05	0.000255	CbGpPWpGaD
Clofarabine—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.11e-05	0.000255	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PSME1—esophageal cancer	1.1e-05	0.000252	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PSME2—esophageal cancer	1.1e-05	0.000252	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—TP53—esophageal cancer	1.08e-05	0.000248	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PTGS2—esophageal cancer	1.07e-05	0.000244	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—EP300—esophageal cancer	9.48e-06	0.000218	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CYP1B1—esophageal cancer	9.46e-06	0.000217	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CYP19A1—esophageal cancer	8.89e-06	0.000204	CbGpPWpGaD
Clofarabine—DCK—Metabolism—EP300—esophageal cancer	8.86e-06	0.000203	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PIK3CA—esophageal cancer	8.51e-06	0.000195	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—HMOX1—esophageal cancer	8.11e-06	0.000186	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ABCB1—esophageal cancer	7.79e-06	0.000179	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PIK3CA—esophageal cancer	7.01e-06	0.000161	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PIK3CA—esophageal cancer	6.55e-06	0.00015	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CREBBP—esophageal cancer	5.2e-06	0.000119	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—NOS3—esophageal cancer	4.66e-06	0.000107	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PTGS2—esophageal cancer	4.26e-06	9.78e-05	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—EP300—esophageal cancer	3.54e-06	8.14e-05	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PIK3CA—esophageal cancer	2.62e-06	6.02e-05	CbGpPWpGaD
